REMS prep pushes back Sage's Zulresso timeline

Sage Therapeutics Inc. (NASDAQ:SAGE) anticipates a June 2019 launch of postpartum depression candidate Zulresso brexanolone after FDA pushed back the PDUFA

Read the full 212 word article

User Sign In